The immune gene expression enables status assessment of the adaptive immunity and immunosuppressive tumor micro environment. Within clinical trials, Immunosign 15 and Immunosign 21 can investigate prognostic and predictive information for cancer immunotherapy development and guide combination therapy strategy.
Proof-of-concept for prognostic and predictive values of Immunosign® 15/21 have been obtained on retrospective cohorts of colorectal cancer patients and have been validated on 9 other cancer types (Galon et al. Immunity 2013, and personal communication).
Immunosign® are performed on Nanostring nCounter®. A dedicated bioinformatics pipeline allows to report a comprehensive analysis of data obtained with Immunosign®. The results generated can be used in clinical trials leading to drug registration.